Chronic Myeloid Leukemia Patients in Prolonged Remission following Interferon-α Monotherapy Have Distinct Cytokine and Oligoclonal Lymphocyte Profile

Interferon alpha for Treatment of Chronic Myeloid Leukemia

(2012) Bengt Simonsson et al.   CURRENT DRUG TARGETS

Anti-Leukemia Activity of In Vitro-Expanded Human Gamma Delta T Cells in a Xenogeneic Ph+ Leukemia Model

(2011) Gabrielle M. Siegers et al.   PLoS One

Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy

(2010) A. Kreutzman et al.   BLOOD

Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy

(2010) Peter Rohon et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

The response to imatinib and interferon-  is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase

(2010) F. Palandri et al.   HAEMATOLOGICA

Sustained Molecular Response With Interferon Alfa Maintenance After Induction Therapy With Imatinib Plus Interferon Alfa in Patients With Chronic Myeloid Leukemia

(2010) Andreas Burchert et al.   JOURNAL OF CLINICAL ONCOLOGY

Pegylated IFN-α2a combined to imatinib mesylate 600mg daily can induce complete cytogenetic and molecular responses in a subset of chronic phase CML patients refractory to IFN alone or to imatinib 600mg daily alone

(2010) Franck E. Nicolini et al.   LEUKEMIA RESEARCH

Imatinib plus Peginterferon Alfa-2a in Chronic Myeloid Leukemia

(2010) Claude Preudhomme et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

(2010) Hagop Kantarjian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia

(2010) Giuseppe Saglio et al.   NEW ENGLAND JOURNAL OF MEDICINE

PR1-Specific T Cells Are Associated with Unmaintained Cytogenetic Remission of Chronic Myelogenous Leukemia After Interferon Withdrawal

(2010) Shreya Kanodia et al.   PLoS One

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

(2009) A Hochhaus et al.   LEUKEMIA

Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy

(2009) S Mustjoki et al.   LEUKEMIA

CD8+ memory T cells predominate over naïve T cells in therapy-free CML patients with sustained major molecular response

(2009) Kensuke Usuki et al.   LEUKEMIA RESEARCH

IFNα activates dormant haematopoietic stem cells in vivo

(2009) Marieke A. G. Essers et al.   NATURE

Natural killer and γδ T cells in haematological malignancies: enhancing the immune effectors

(2009) Jérôme Rey et al.   TRENDS IN MOLECULAR MEDICINE

Primitive quiescent CD34+ cells in chronic myeloid leukemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomib

(2008) A. S. M. Yong et al.   BLOOD

Does chemotherapy modify the immune surveillance of hematological malignancies?

(2008) A J Barrett et al.   LEUKEMIA